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June Supplement 201196S Abstractsinstitutions, and vascular surgeons was reviewed and resul-
tant conclusions derived.
Results: The incidence of stroke in seniors with 60%
carotid stenosis with best medical management at the time
in the Asymptomatic Carotid Arteriosclerotic Study was
11% and should be at least that with no discovery or
management. Screening 18,446 seniors in the AVA pro-
gram yielded 7.4% with possible 60% carotid stenosis, far
more than the 1% figure used by the USPSTF in recom-
mending against screening. Since a stroke rate of 2% is
widely available with CEA, 200,000 strokes could be pre-
vented by screening the senior Medicare population. The
cost of a stroke averages $145,000 and the cost of carotid
screening, evaluation, and management to prevent one
stroke is $82,193 resulting in a saving of $64,807. Carotid
screening of seniors could save over 13 billion dollars
annually for the Medicare system.
Conclusions: Stroke remains the leading cause of dis-
ability, and the 3rd leading cause of death. Since treatment
of stroke is less than ideal, emphasis on primary stroke
prevention is appropriate, but strokes cannot be reduced if
the silent leading immediate cause of strokes, carotid artery
disease, is not recognized and managed. Management by
the best means for the patient-CEA, CAS, or medically-has
to bebetter thanno recognition andnomanagement.Carotid
screening should be done. Since vascular surgeons are the
most knowledgeable in carotid disease and application of the
treatment options, screening nationally for carotid disease
should be presented to and discussed by the SVS.
Author Disclosures: G. S. Lavenson: Nothing to dis-
close.
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Functional Outcome of Arteriovenous Fistula Varies
with Age: Analysis of a VA Health Care System Practice
Elsie Gyang1, Fritz Bech2. 1Stanford University School of
Medicine, Stanford, CA; 2Palo Alto VA Health Care Sys-
tem, Palo Alto, CA
Objectives: To assess the relationship between age and
arteriovenous fistula (AVF) usability in Veteran patients.
Methods: Retrospective review of all AVFs, 2003-
2010. Age was considered by group (60, 60-75, 75)
and as a continuous variable.
Results: 201 AVFs were created in 171 patients (mean
age 63.7/ 9.5; male 99%; non-white 48%; active dialy-
sis 55%). 45%were wrist fistulas, 54% upper arm, 31% re-do.
Older groups had more CAD (19% of 60, versus 51% of
60-75, versus 55% of 75; p  0.001) and more CHF
(12% versus 35% versus 45%; p  0.001). There were no
differences by age group in diabetes, hypertension, PAD,
BMI, vein diameter, AVF location, re-do or dialysis cathe-
ter status. Mean follow-up was 32 months (range 6-79).
32% of AVFs were in use at 6 months. Success de-
creased with age: 50% in patients60, versus 25% in 60-75,
versus 21% in those 75 (log-rank test, p  0.007). A pultivariable Cox model identified age as the sole indepen-
ent predictor of outcome (HR 0.96, 95% CI 0.93-0.99).
4% of AVFs were used eventually, more frequently in the
ounger group (68% versus 44% and 47%; log-rank test,
 0.018). 14% of patients 60 died before the AVF was
ver used, compared with 30% and 34% in the older groups.
edian patient survival was 85, 53, and 26months, respec-
ively (log-rank test, p 0.002).
Conclusions: A functional AVF is harder to achieve in
lder Veterans, whose median survival is limited. Prosthetic
V grafts may offer superior permanent dialysis access for
any of these patients.
uthor Disclosures: F. Bech: Nothing to disclose; E.
yang: Nothing to disclose.
R10.
alloon Angioplasty versus Stent Placement in the
reatment of Venous Anastomotic Stenoses of Hemo-
ialysis Grafts Following Surgical Thrombectomy
ohn D. Kakisis, Efthimios D. Avgerinos, Triantafyllos G.
iannakopoulos, Konstantinos G. Moulakakis, Anastasios
apapetrou, Christos D. Liapis. Department of Vascular
urgery, Athens University Medical School, “Attikon”
ospital, Athens, Greece
Objectives: Most of the arteriovenous hemodialysis
rafts fail within eighteen months post-implantation, most
ommonly due to intimal hyperplasia at the venous anasto-
osis. The aim of our study was to compare balloon
ngioplasty versus bare metal stent placement in the treat-
ent of venous anastomotic stenosis following thrombec-
omy of upper arm straight arteriovenous hemodialysis
rafts.
Methods: Between 2/2007 and 12/2010, 61 patients
ith a first-time thrombosis of an upper arm straight arte-
iovenous hemodialysis graft were admitted to our hospital.
wenty-eight (46%) of these patients, treated before
/2008, underwent thrombectomy plus balloon angio-
lasty of the venous anastomosis (group A), whereas the
est 33 (54%) patients, treated after 7/2008, underwent
raft thrombectomy plus angioplasty with self-expanding
itinol stent placement (Group B). Primary patency, de-
ned as the time period from graft thrombectomy plus
ngioplasty to the next graft failure, was estimated using
aplan-Meier analysis and compared between the two
roups with the log-rank test.
Results: In group A, primary patency was 32% at 3
onths, 24% at 6months and 14% at 12months. The respec-
ive values in group B were 85%, 63% and 49% (Figure).
rimary patency was significantly better in group B than in
roupA (p0.001, log rank test).Median patency in groupA
as 2 months, whereas in group B it was 12 months.
Conclusions: Graft thrombectomy plus angioplasty
ith self-expanding nitinol stent placement provides signif-
cantly higher patency rates compared with thrombectomy
lus plain balloon angioplasty of the venous anastomosis.
o
c
0
c
f
a
l
p
A
A
A
S
G
P
G
N
t
o
o
o
F
R
T
E
P
P
E
v
f
a
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 17S Abstracts 97SAuthor Disclosures: E. D. Avgerinos: Nothing to dis-
close; T. G. Giannakopoulos: Nothing to disclose; J. D.
Kakisis: Nothing to disclose; C. D. Liapis: Nothing to
disclose; K. G. Moulakakis: Nothing to disclose; A. Pa-
papetrou: Nothing to disclose.
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Familial AAA: High Prevalence and Decreased Cardiac
Risk Factors
Koen M. van de Luijtgaarden, Sanne E. Hoeks, Erik J.
Bakker, Michiel T. Voute, Niels J. Ravensbergen, Hence J.
Verhagen, Danielle Majoor Krakauer, Don Poldermans.
Vascular Surgery, Erasmus MC, Rotterdam, Netherlands
Objectives: The aim of this study was to investigate the
prevalence of familial abdominal aortic aneurysms (AAA) in
a tertiary medical center and to appreciate common cardio-
vascular risk factors for their association with sporadic and
familial AAA.
Methods: Family histories were ascertained by ques-
tionnaire from 405 AAA patients (total 7955 relatives)
treated between 1990-2009 (91% men; age at surgery
67,58.1 years). Familial AAA was defined as having one
or more first or second degree family members suffering
from AAA. Cardiac risk profile was assessed with the Lee’s
Revised Cardiac Risk Index. Univariable en multivariable
analysis were performed to assess differences in atheroscle-
rotic risk factors between sporadic and familial AAA
patients.
Results: Familial AAA was reported in 106 patients
(26%) and in 87 patients (82%) first-degree relatives were
affected. Using multivariable analysis, familial AAA was
significantly associated with lower age of the patient at
diagnosis (OR 0.94; 95%CI 0.91-0.97), reduced incidence pf hypertension (OR 0.35; 95%CI 0.21-0.58) and de-
reased cardiac risk profile (1 risk factor OR 0.60; 95%CI
.35-1.02; 2 risk factors OR 0.49; 95%CI 0.24-0.99)
ompared to patients with sporadic AAA.
Conclusions: Our data show a high proportion of
amilial AAA. The familial AAA patients were diagnosed at
younger age, had a reduced incidence of hypertension and
ess cardiac risk factors. These findings emphasize the im-
ortance of a genetic component in the pathogenesis of
AA and suggest the need for further screening in familial
AA families.
uthor Disclosures: E. J. Bakker: Nothing to disclose;
. E. Hoeks: Dutch foundation ”Lijf en Leven”, Research
rants; D. Majoor Krakauer: Nothing to disclose; D.
oldermans: Merck, Research GrantsNovartis, Research
rantsMedtronic,Research Grants; N. J. Ravensbergen:
othing to disclose; K. M. van de Luijtgaarden: Nothing
o disclose; H. J. Verhagen: Cook, Consulting fees or
ther remuneration (payment)Medtronic,Consulting fees
r other remuneration (payment) Gore, Consulting fees or
ther remuneration (payment);M. T. Voute: DutchHeart
oundation, Research Grants.
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rends in the Utilization of Endovascular Therapy for
lective and Ruptured Abdominal Aortic Aneurysm
rocedures across Canada: A Cohort Study
rasad Jetty1, Don Husereau2. 1Division of Vascular and
ndovascular Surgery, The Ottawa Hospital and the Uni-
ersity of Ottawa, Ottawa, ON, Canada; 2Canadian Agency
or Drugs and Technologies in Health, Ottawa, ON, Can-
da
Objectives: While randomized trials have shown im-
roved operative mortality with Endovascular Aneurysm
